quinidine has been researched along with bufuralol in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 6 (30.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Gonzalez, FJ; Hardwick, JP; Inaba, T; Kalow, W; Tyndale, RF | 1 |
| Dayer, P; Eichelbaum, M; Kronbach, T; Meyer, UA | 1 |
| Blair, IA; Guengerich, FP; Müller-Enoch, D | 1 |
| Guengerich, FP; Stöckigt, J; Strobl, GR; von Kruedener, S; Wolff, T | 1 |
| Halliday, RC; Jones, BC; Kitteringham, NR; Park, BK; Smith, DA | 1 |
| Gilham, D; Paine, MJ; Roberts, GC; Wolf, CR | 1 |
| Mankowski, DC | 1 |
| Bolten, S; Burton, EG; Engel, L; Maziasz, TJ; Paulson, SK; Reitz, B; Schoenhard, GL; Yan, B | 1 |
| Colby, HD; Hayes, JR; Longhurst, PA; Nowak, DM; Voigt, JM; Zhang, X | 1 |
| Gillam, EM; Guengerich, FP; Hanna, IH; Martin, MV | 1 |
| Doehmer, J; Eichelbaum, MF; Krebsfaenger, N; Mürdter, TE; Zanger, UM | 1 |
| Guo, B; He, MM; Li, C; Liu, H; Shen, H; Wang, L; Wrighton, SA | 1 |
| Chen, Y; Subramanian, R; Zhu, X | 1 |
20 other study(ies) available for quinidine and bufuralol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.
Topics: Animals; Blotting, Western; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Immunochemistry; In Vitro Techniques; Kinetics; Liver; Quinidine; Rats; Rats, Inbred Strains; Sparteine | 1990 |
Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Topics: Adult; Aged; Binding, Competitive; Cytochrome P-450 Enzyme System; Debrisoquin; Ethanolamines; Humans; Hydroxylation; Isoenzymes; Isoquinolines; Kinetics; Microsomes, Liver; Middle Aged; Phenotype; Polymorphism, Genetic; Quinidine; Sparteine | 1987 |
Oxidation of quinidine by human liver cytochrome P-450.
Topics: Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Ethanolamines; Humans; Hydroxylation; In Vitro Techniques; Microsomes, Liver; Nifedipine; Oxidation-Reduction; Quinidine; Rats | 1986 |
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
Topics: Alkaloids; Computer Simulation; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Ethanolamines; Humans; Indoles; Microsomes, Liver; Mixed Function Oxygenases; Models, Molecular; Molecular Conformation; Molecular Structure; Quinidine; Quinolines; Secologanin Tryptamine Alkaloids; Yohimbine | 1993 |
An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.
Topics: Alkylation; Antimalarials; Cloning, Molecular; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Ethanolamines; Felodipine; Genotype; Humans; Hydroxylation; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Phenanthrenes; Quinidine; Tacrine | 1995 |
Functional high level expression of cytochrome P450 CYP2D6 using baculoviral expression systems.
Topics: Adrenergic beta-Antagonists; Animals; Baculoviridae; Cells, Cultured; Cloning, Molecular; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Ethanolamines; Gene Expression Regulation; Humans; Mixed Function Oxygenases; NADPH-Ferrihemoprotein Reductase; Promoter Regions, Genetic; Quinidine; Rats; Recombinant Proteins; Spectrophotometry; Spodoptera | 1996 |
The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Topics: Adrenergic beta-Antagonists; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Ethanolamines; Humans; In Vitro Techniques; Kinetics; Mephenytoin; Microsomes, Liver; Mixed Function Oxygenases; Quinidine; Stereoisomerism; Substrate Specificity | 1999 |
Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib.
Topics: Animals; Celecoxib; Cloning, Molecular; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme System; Dogs; Ethanolamines; Female; Humans; Isoenzymes; Male; Membrane Proteins; Microsomes, Liver; Polymorphism, Genetic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinidine; Sulfonamides | 1999 |
Bufuralol metabolism by guinea pig adrenal and hepatic microsomes.
Topics: Adrenal Glands; Adrenergic beta-Antagonists; Animals; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Ethanolamines; Guinea Pigs; Hydrocortisone; Magnetic Resonance Spectroscopy; Male; Microsomes, Liver; Quinidine | 2001 |
Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.
Topics: Amines; Amino Acid Substitution; Binding Sites; Catalysis; Cytochrome P-450 CYP2D6; Ethanolamines; Glutamic Acid; Glutamine; Humans; Hydroxylation; Methylation; Mutagenesis, Site-Directed; Oxidation-Reduction; Protein Binding; Quinidine; Recombinant Proteins; Spiro Compounds; Static Electricity; Substrate Specificity; Sulfonamides; Tyramine | 2003 |
V79 Chinese hamster cells genetically engineered for polymorphic cytochrome P450 2D6 and their predictive value for humans.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Cell Line; Cricetinae; Cricetulus; Cytochrome P-450 CYP2D6; Drug Interactions; Ethanolamines; Gene Expression Regulation, Enzymologic; Genetic Engineering; Genetic Variation; Genetic Vectors; Hydroxylation; Polymorphism, Genetic; Quinidine; RNA, Messenger; Selective Estrogen Receptor Modulators; Tamoxifen; Transfection | 2003 |
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Topics: Atomoxetine Hydrochloride; Cocaine; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dextromethorphan; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Hydroxylation; Imipramine; Kinetics; Microsomes; Molecular Structure; Nortriptyline; Polymorphism, Single Nucleotide; Propylamines; Quinidine; Recombinant Proteins; Thioridazine; Tramadol | 2007 |
Comparison of information-dependent acquisition, SWATH, and MS(All) techniques in metabolite identification study employing ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry.
Topics: Algorithms; Animals; Biotransformation; Chlorpromazine; Chromatography, High Pressure Liquid; Ethanolamines; Microsomes, Liver; Midazolam; Oxidation-Reduction; Quinidine; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |